Vereinbarung nach § 130c Abs. 1 SGB V für das Arzneimittel Epclusa mit der Wirkstoffkombination Sofosbuvir/Velpatasvir

Buyer

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen

Winners

Gilead Sciences GmbH

Contract value

no value published

Bids received

1

Published

27 Jul 2026

Awarded

14 Jul 2026

Contract start

1 Sept 2026

Contract end

31 Aug 2028stated

Sector

Medical equipment and pharmaceuticals

Region

Sachsen (DED21)

Source

Original notice on TED (520789-2026)

More awards from this buyer